Overview

Smoking Cessation Interventions for People Living With HIV in Nairobi, Kenya

Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The proposed study will use a factorial design to evaluate the most promising and accessible behavioral and pharmacologic treatments aimed at achieving maximal efficacy for smoking cessation among people living with HIV who smoke. The study will randomize 300 participants people living with HIV , who smoke and who are receiving care in a methadone maintenance program in Nairobi, Kenya to one of the following 4 conditions: (1) bupropion + Positively Smoke Free (an 8 session tailored behavioral intervention for people living with HIV smokers); (2) bupropion + Standard of Care (brief advice to quit); (3) Placebo + Positively Smoke Free; and (4) Placebo + Standard of Care.
Phase:
Phase 3
Details
Lead Sponsor:
University of Maryland
University of Maryland, Baltimore
Treatments:
Bupropion